OIPE

PTO/SB/01A (10-00).

WAR 2 5 2002 Approved for use through 10/31/2002. OMB 0651-0032. U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF OVARIAN CANCER				
As the below named inventor(s), I/we declare that: This declaration is directed to:					
☐ The attache	ed application, or				
=	No. <u>10/015,219</u> , filed on <u>December</u>	12, 2001,			
	nded on (if applicable);				
I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;					
I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;					
I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including material information which became available between the filing date of the prior application and the National or PCT International filing date of the continuation-in-part application, if applicable; and					
All statements made herein of my/our own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.					
FULL NAME OF INVEN	TOR(S)				
Inventor one: Paul	A. Algate	Citizen of:	United Kingdom		
Signature:	Holgon	Date:	02/11/02		
Inventor two:		Citizen of:			
Signature:		Date:			
Inventor three:		Citizen of:			
Signature:		Date:			
Inventor four:		Citizen of:			
Signature:		Date:			
Additional inventors are being named on additional form(s) attached hereto.					

Burden Hour Statement: This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is used by the public to file (and the PTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This form is estimated to take 1 minute to complete. This time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

4

Please type a plus sign (+) inside this box



MAIL NO. EV020612761US

PTO/SB/81 (10-00)

Approved for use through 10/31/2002. OMB 0651-0035

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

ECTION AND POWER OF **ATTORNEY OR AUTHORIZATION OF AGENT**

Application Number	10/015,219
Filing Dat	December 12, 2001
First Named Inv ntor	Paul A. Algate
Group Art Unit	•
Examiner Name	
Attorney Docket Number	210121.493C1

I hereby ap Practition OR Practition	ers at Se	ed IP Law Group PLLC ed below:	· .		00500 PATENT TRADEMARK	OFFICE
Г		Nama		Pogistratio	n Numbor	l ·
-		Name		Registratio	n Number	·
as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the Patent and Trademark Office connected therewith.						
Please change the correspondence address for the above-identified application to: The above-mentioned Customer Number. OR						
Firm or	I Name	Name				
Address	_					
Address						
City .			State		ZIP	
Country			-			
Telephone			Fax		•	
I am the: ☐ Applicant/Inventor. ☐ Assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96). ☐ As assignee of record of the entire interest hereby elect, under 37 C.F.R. § 3.71, to prosecute the application to the exclusion of the inventor						
SIGNATURE of Applicant or Assignee of Record						
Name	Kathleen Nora McKereghan					
Signature	Signature alphanic					
Date 22 7eb 2002						
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.						
*Total of _	*Total of forms are submitted.					
ourden Hour Statement: This form is estimated to take 3 minutes to complete. Time will vary depending upon the needs of the individual case. Any						

Comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.



PTO/SB/96 (08-00) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE der the Paperwork Reduction Act of 1995, 'no persons are required to respond to a collection of information unless it displays a valid OMB control number.

MARK	STATEMENT UNDER 37 CFR 3.73(b)				
Applicant/Patent Owner:	Paul A. Algate				
Application No./Patent No.:	10/015,219	Filed/Issue Date: December 12, 2001			
		HE THERAPY AND DIAGNOSIS OF			
OVARIAN CANCE	R				
Coriva Cornora	ition	a corporation			
(Name of Assign		(Type of Assignee, e.g., corporation, partnership,			
states that it is:		university, government agency, etc.)			
1. X the assignee of the en	tire right, title, and intere	est; or			
2. an assignee of an und	livided part interest				
in the patent application/pate	ent identified above by v	irtue of either:			
	•	ent application/patent identified above.			
The assignment was r	ecorded in the United S	tates Patent and Trademark Office at			
Reel, Frame OR	, or for which a co	py thereof is attached.			
	e inventor(s) of the pate	ent application/patent identified above, to the			
current assignee as sl					
1. From:	•	Го:			
	recorded in the United S , or for which a co	States Patent and Trademark Office at oppy thereof is attached			
2. From:	· ·	Го:			
	The document was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached				
3. From:	-	Го:			
The document was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.					
Additional documents in the chain of title are listed on a supplemental sheet.					
X Copies of assignments or other documents in the chain of title are attached.					
	on in accordance with 37 CFF	nent or a true copy of the original document) must be R Part 3, if the assignment is to be recorded in the records			
· ·	- ·	uthorized to act on behalf of the assignee.			
22 Feb 20 Date	002	Kathleen Nora McKereghan			
Date		Typed or printed name			
	Cal	MOL N. MOV. Signature			
	Seni	or Vice President, General C unsel and Secretary			
		Title			

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

EXPRESS MAIL NO. EV020612761US

PATENT

MAR 25 2002

N THE UNITED STATES PATENT AND TRADEMARK OFFICE

: Paul A. Algate

Filed: December 12, 2001

For : COMPOSITIONS AND METHODS FOR THE THERAPY AND

DIAGNOSIS OF OVARIAN CANCER

Docket No.

210121.493C1

Date

: March 25, 2002

Box Missing Parts U.S. Patent and Trademark Office P.O. Box 2327 Arlington, VA 22202

DECLARATION

Sir:

I, Lawrence Teague, in accordance with 37 C.F.R. § 1.821(f) do hereby declare that, to the best of my knowledge, the content of the paper entitled "Sequence Listing" and the computer readable copy contained within the floppy disk are the same.

I declare further that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Dated this 25th day of March, 2002.

Lawrence Teague

Biotechnology Paralegal

701 Fifth Avenue, Suite 6300 Seattle, WA 98104-7092 (206) 622-4900 FAX (206) 682-6031